DE69320485D1 - VERWENDUNG VON MELATONIN in niedrigen oralen Dosen ZUM HERBEIFÜHREN VON SCHLAF - Google Patents

VERWENDUNG VON MELATONIN in niedrigen oralen Dosen ZUM HERBEIFÜHREN VON SCHLAF

Info

Publication number
DE69320485D1
DE69320485D1 DE69320485T DE69320485T DE69320485D1 DE 69320485 D1 DE69320485 D1 DE 69320485D1 DE 69320485 T DE69320485 T DE 69320485T DE 69320485 T DE69320485 T DE 69320485T DE 69320485 D1 DE69320485 D1 DE 69320485D1
Authority
DE
Germany
Prior art keywords
melatonin
oral doses
low oral
induce sleep
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69320485T
Other languages
English (en)
Other versions
DE69320485T2 (de
Inventor
Richard J Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of DE69320485D1 publication Critical patent/DE69320485D1/de
Application granted granted Critical
Publication of DE69320485T2 publication Critical patent/DE69320485T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69320485T 1992-10-01 1993-09-29 VERWENDUNG VON MELATONIN in niedrigen oralen Dosen ZUM HERBEIFÜHREN VON SCHLAF Expired - Fee Related DE69320485T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95530492A 1992-10-01 1992-10-01
US08/093,317 US5449683A (en) 1992-10-01 1993-07-16 Methods of inducing sleep using melatonin
PCT/US1993/009273 WO1994007487A1 (en) 1992-10-01 1993-09-29 Use of melatonin to induce sleep

Publications (2)

Publication Number Publication Date
DE69320485D1 true DE69320485D1 (de) 1998-09-24
DE69320485T2 DE69320485T2 (de) 1999-04-01

Family

ID=26787395

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69320485T Expired - Fee Related DE69320485T2 (de) 1992-10-01 1993-09-29 VERWENDUNG VON MELATONIN in niedrigen oralen Dosen ZUM HERBEIFÜHREN VON SCHLAF

Country Status (9)

Country Link
US (2) US5449683A (de)
EP (1) EP0663825B1 (de)
JP (1) JP3133760B2 (de)
AT (1) ATE169816T1 (de)
CA (1) CA2146151C (de)
DE (1) DE69320485T2 (de)
DK (1) DK0663825T3 (de)
ES (1) ES2123064T3 (de)
WO (1) WO1994007487A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) * 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5530012A (en) 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP0728738A1 (de) * 1995-02-24 1996-08-28 Bristol-Myers Squibb Company Tetralinyl- und Indanyl-Ethylamide mit melatoninerger Aktivität
US5661186A (en) * 1995-02-24 1997-08-26 Bristol-Myers Squibb Co. Tetralinyl-and indanyl-ethylamides
US5736578A (en) * 1995-06-06 1998-04-07 Bristol-Myers Squibb Company Ethylamido fluorenes and improved method of making same
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
US5753709A (en) * 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
AU6241796A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
DE19713141A1 (de) * 1996-03-29 1997-10-30 Labtec Gmbh Transdermales System mit Melatonin
US5808151A (en) * 1996-04-17 1998-09-15 Bristol-Myers Squibb Company Biphenylamido derivatives as melatonergic agents
EP1027043B1 (de) * 1996-12-10 2004-11-10 Bristol-Myers Squibb Company Benzodioxol, benzofuran, dihydrobenzofuran und benzodioxan melatonergische agentien
US5948817A (en) * 1997-03-05 1999-09-07 Bristol-Myers Squibb Company Polycyclic ethyl alkylamide melatonergic agents
EP0867181A1 (de) * 1997-03-26 1998-09-30 Franciscus Wilhelmus Henricus Maria Merkus Melatoninhaltiges Nasalpräparat
NZ501321A (en) * 1997-03-26 2001-04-27 Franciscus W Nasal Melatonin composition
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US6028112A (en) * 1997-05-23 2000-02-22 Bristol-Myers Squibb Company Spirocyclopropyl fluorenes as melatonergic agents
AU2333099A (en) * 1998-03-20 1999-10-18 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
JP2002516859A (ja) 1998-06-05 2002-06-11 ブリストルーマイヤーズ スクイブ カンパニー メラトニン作動性薬剤であるヘテロ環シスシクロプロパン誘導体
AU763963B2 (en) 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
CA2357114C (en) * 2001-03-22 2010-06-29 Pooger Properties Ltd. Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
CA2500198A1 (en) * 2002-09-26 2004-04-08 Pooger Properties Limited Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder
US6703412B1 (en) 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US20070207134A1 (en) * 2004-03-31 2007-09-06 Calpis Co., Ltd Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm
US8852656B2 (en) * 2004-04-06 2014-10-07 Taiyokagaku Co., Ltd. Sleep improvement composition
EP1749234A4 (de) 2004-04-23 2009-04-29 Physician Engineered Products Am kopf angebrachte fotoeffektive einrichtung
US7546165B2 (en) * 2005-12-19 2009-06-09 Cardiac Pacemakers, Inc. Interconnections of implantable lead conductors and electrodes and reinforcement therefor
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
US20080171085A1 (en) * 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US10369310B2 (en) * 2014-03-05 2019-08-06 ResMed Pty Ltd Method and apparatus for treatment of respiratory disorders
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos
IT201900002913A1 (it) 2019-03-01 2020-09-01 Nicola Pescosolido Composto utile per il trattamento del glaucoma
US11833182B2 (en) 2021-08-10 2023-12-05 Shaklee Corporation Sleep product

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5557563A (en) * 1978-10-21 1980-04-28 Hoechst Ag Melatonine nasal application composition
EP0126630B1 (de) * 1983-05-18 1987-09-16 Monash University Verwendung von Melatonin zur Herstellung eines Arzneimittels
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
JPH0474135A (ja) * 1990-07-13 1992-03-09 Kanegafuchi Chem Ind Co Ltd 点眼組成物
IT1243193B (it) * 1990-08-10 1994-05-24 Medea Res Srl Composizioni farmaceutiche orali a base di melatonina
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
NZ244760A (en) * 1991-10-18 1997-02-24 Alza Corp Transdermal administration of melatonin; device comprising melatonin with skin permeation enhancer and melatonin impermeable backing on skin-distal device surface
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
US5641801A (en) 1997-06-24
DK0663825T3 (da) 1999-05-25
CA2146151C (en) 1997-09-02
EP0663825A1 (de) 1995-07-26
ATE169816T1 (de) 1998-09-15
JPH08502259A (ja) 1996-03-12
EP0663825B1 (de) 1998-08-19
WO1994007487A1 (en) 1994-04-14
ES2123064T3 (es) 1999-01-01
US5449683A (en) 1995-09-12
DE69320485T2 (de) 1999-04-01
JP3133760B2 (ja) 2001-02-13

Similar Documents

Publication Publication Date Title
ATE169816T1 (de) Verwendung von melatonin in niedrigen oralen dosen zum herbeiführen von schlaf
NO952469D0 (no) Terapautisk kombinasjon som inneholder interferon
DK162986D0 (da) Terapeutisk middel i enhedsdosisform
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
DK0562041T3 (da) Undermættet transdermal lægemiddeludleveringsanordning, der udviser forøget lægemiddelflux
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE3687099D1 (de) Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
HK1003980A1 (en) Dosage form for dispensing drug and human therapy
DK0946151T3 (da) Doseringsform med stigende dosisfrigivelse
DK505787A (da) Catecholderivater samt forebyggende og terapeutisk praeparat omfattende samme mod regressive sygdomme i centralnervesystemet
IT1189097B (it) Sali di diacetilreina e loro impiego terapeutico nel trattamento dell'artrosi
FI851686L (fi) Redskap foer anvaendning vid behandling av osteoporosis.
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
NO145789C (no) Nye piperidinforbindelser med plaquehemmende virkning og for anvendelse i preparater for behandling av munnhule og tannflater
ATE76579T1 (de) Interferon-zusammensetzungen.
DK332489A (da) Forbindelser med bronkodilatorisk virkning
SE7700626L (sv) Patientstol for ltandbehandling
ATE229981T1 (de) Glykolisierte cytokine
NO864932D0 (no) Anordning for injeksjon av behandlingsprodukter i broenner.
ATE78695T1 (de) Verwendung und mittel zur verminderung der nebenwirkungen von tnf.
ES2051788T3 (es) Un producto farmaceutico.
ATE144712T1 (de) Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
NO920306D0 (no) Nye indolonaftyridiner med terapeutisk virkning

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee